Navigation Links
Indivumed Sells Inostics, the plasma-DNA Company, to Sysmex and Expands its Clinical Research Service and Patient Diagnostics Business

HAMBURG, Germany, September 25, 2013 /PRNewswire/ --

Indivumed GmbH ("Indivumed"), based in Hamburg, Germany, announces that 100% of all shares of Inostics GmbH and its Baltimore, US-based subsidiary Inostics Inc. ("Inostics"), have been sold to Sysmex Corporation (Headquarter in Kobe, Japan).

Inostics possesses advanced genetic testing technologies, such as ultra-sensitive digital PCR technology for detecting cancer cell DNA directly from blood - a "liquid biopsy" process as opposed to tissue testing. By acquiring this technology, Sysmex plans to develop on a global basis assay services that Inostics already provides. Sysmex's companion diagnostics activities in collaboration with pharmaceutical companies will be enhanced as well.

In 2008, following a five year collaboration with Dr. Bert Vogelstein and his team at Johns Hopkins University in Baltimore, MD, Indivumed and the scientists at Johns Hopkins University together founded Inostics GmbH in Hamburg, Germany, to commercialize the "BEAMing-Technology". "Having established a solid foundation to enable the rapid growth of Inostics, the overwhelming acceptance of this groundbreaking technology by pharmaceutical companies and the medical community demanded a global growth strategy and search for a strategic partner. We are delighted to have found with Sysmex the ideal partner for the next development phase," comments Prof. Hartmut Juhl, CEO of Indivumed and Inostics.

"With Sysmex, we expect achieving our goal to make Inostics technology the leading approach for DNA-based cancer diagnostics for the worldwide benefit of cancer patients. The fact that Sysmex has its European Headquarter in the Hamburg area facilitates a smooth transition and an undelayed continuation of Inostics business" says Dr. Frank Diehl, co-founder of Inostics, who continues to work for Inostics as Chief Scientific Officer and Managing Director.

Following the closing of the transaction, Indivumed will independently expand its tissue-based clinical research service business leveraging a comprehensive and very high quality tumor-biobank and its well-established prowess in the analysis of proteins and cancer pathways for drug development and patient diagnostics.

JMP Securities LLC acted as financial advisor and Freshfields Bruckhaus Deringer LLP served as legal counsel to Inostics and its shareholder in the transaction.

About Indivumed GmbH

Indivumed GmbH, a privately hold biotech company, was founded 2002 in Hamburg, Germany, to promote the development and clinical implementation of individual cancer therapies. Based on a highly standardized tumor biobank and a unique clinical infrastructure with clinical partners in Germany and the US, Indivumed offers a broad range of specialized research services to biopharmaceutical companies and academia and performs biomarker research and development. With its subsidiary IndivuTest GmbH, Indivumed provides high-quality-tissue based tumor analysis to patients and started an initiative with oncologists in Germany and the US to improve personalized cancer therapy strategies in the clinical routine.

For more information (also about Inostics and IndivuTest) please visit

About Sysmex Corporation

Sysmex Corporation (Headquarter: Kobe, Japan), a listed company at the Tokyo Stock Exchange market, supports human health. Sysmex is an integrated company, developing and manufacturing the instruments, reagents and software that are needed for in-vitro diagnostics, and providing the necessary sales and support networks. Sysmex is expanding operations, augmenting traditional strength in hematology with non-hematology fields such as immunochemistry and hemostasis, as well as the life science field. Sysmex is leveraging its proprietary technologies to create new testing and diagnostic technologies that aim to ensure optimal healthcare for all.

For more information please visit

Press contact:
Swantje Niphut
Phone: +49(0)40-413383-0

SOURCE Indivumed GmbH
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Geisinger Partners With Indivumed for Personalized Medicine Initiative
2. Pure Garcinia Cambogia Extract from Zen Health Labs Sells Out Three Weeks after its Launch on Amazon
3. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
4. Microsofts Surface Pro Tablet Makes its Debut and Sells Out Fast; the Company was One of the Few to Defy the Dows Loss Yesterday
5. Apama Medical, A Shifamed Portfolio Company, Closes $3.2M Series A-1 Financing Round
6. ParagonRx, An inVentiv Health Company, Names Former U.S. Food And Drug Administration Official To Position Of Chief Medical Officer
7. Pioneering Medical Technology Company, Optivus Proton Therapy, Inc., Celebrates 20th Anniversary
8. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
9. Nucletron, an Elekta company, to Debut New Flexitron Brachytherapy Afterloading Platform at 2013 American Brachytherapy Society Meeting
10. Accordant Health Services, a CVS Caremark Company, Receives URAC Case Management Accreditation
11., a Skolkovo Participant Company, Celebrates Anniversary of DNA Discovery with Launch of New Social Network
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY USA ... continues to provide evidence demonstrating the accuracy of its ... Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in ... both the Company,s GLUCOCARD ® 01 meter and ... accuracy requirements. The ability to accurately measure glucose levels ...
(Date:11/25/2015)... 25, 2015 Kitov Pharma ... KTOV), a biopharmaceutical company focused on the development of ... conditions, today announced the closing of its previously announced ... ADSs ), each representing 20 ordinary shares of the ... The ADSs and warrants were issued in a fixed ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Trovagene, ... molecular diagnostics, today announced that Chief Executive Officer Antonius ... at the 27 th Annual Piper Jaffray Healthcare ... Conference at the New York Palace Hotel in ... 2015 at 1:30 p.m. EST. Mr. Schuh will be ...
Breaking Medicine Technology:
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk ... roadways has dropped below 10,000 for the first time since 2011. In 2014, there ... According to data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people ...
(Date:11/25/2015)... ... November 25, 2015 , ... In honor of ... Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension (PH) patients ... by the public, will receive special recognition throughout 2016 as part of PHA’s ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract ... significant expansion of its current state of the art research, development and manufacturing ... to increase its manufacturing capacity as well as to support its clients’ growing ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of the common symptoms of ... and dry skin. But many people who find their cholesterol levels and weight are ... their thyroid, especially if they don’t have any of the other symptoms. , Thyroid ...
Breaking Medicine News(10 mins):